Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages 18 to 70 years.~* Participants infected with hepatitis C virus (HCV) genotype 1, 2, or 3, with no previous exposure to an interferon formulation (ie, interferon-alpha, pegylated interferon-alpha) ribavirin, or other HCV-specific direct-acting antiviral (including daclatasvir and PSI-7977).~* Patients should have chronic hepatitis C genotype 1a, 1b, 2, or 3 as documented by: positive test results for anti-HCV antibody; HCV RNA; or a HCV genotype at least 6 months prior to screening, and HCV RNA and anti-HCV antibody at the time of screening.~Exclusion Criteria:~* Evidence of a medical condition associate with chronic liver disease other than HCV.~* History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis.~* History of hemophilia.~* History of torsade de pointes.~* Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment.~* History of gastrointestinal disease or surgical procedure (except cholecystectomy).~* History of clinically significant cardiac disease.~* Blood transfusion within 4 weeks prior to study drug administration.~* Poor venous access.~* Any other medical, psychiatric, and/or social reason which, in the opinion of the Investigator, would make the candidate inappropriate for participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A: PSI-7977 + Daclatasvir (Type: EXPERIMENTAL): Genotype 1a or 1b
- Treatment B: PSI-7977 + Daclatasvir (Type: EXPERIMENTAL): Genotype 2 or 3
- Treatment C: PSI-7977 + Daclatasvir (Type: EXPERIMENTAL): Genotype 1a or 1b
- Treatment D: PSI-7977 + Daclatasvir (Type: EXPERIMENTAL): Genotype 2 or 3
- Treatment E: PSI-7977 + Daclatasvir + Ribavirin (Type: EXPERIMENTAL): Genotype 1a or 1b
- Treatment F: PSI-7977 + Daclatasvir+ Ribavirin (Type: EXPERIMENTAL): Genotype 2 or 3
- Treatment G: PSI-7977 + Daclatasvir (Type: EXPERIMENTAL): Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b
- Treatment H: PSI-7977 + BMS-790052 + Ribavirin (Type: EXPERIMENTAL): Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b
- Treatment I: PSI-7977 + Daclatasvir (Type: EXPERIMENTAL): Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b
- Treatment J: PSI-7977 + Daclatasvir + Ribavirin (Type: EXPERIMENTAL): Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b

Based on this trial design, predict the completion outcome and termination type (if applicable).